| Mrs Katherine Elizabeth Carrera, NNP | |
|
3340 Providence Dr, Suite 366, Anchorage, AK 99508-4627 | |
| (907) 563-3026 | |
| Not Available |
| Full Name | Mrs Katherine Elizabeth Carrera |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Neonatal, Critical Care |
| Location | 3340 Providence Dr, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245464551 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LN0005X | Nurse Practitioner - Neonatal, Critical Care | 345 (Alaska) | Primary |
| Entity Name | Pediatrix Medical Group Of Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083711790 PECOS PAC ID: 4486634417 Enrollment ID: O20040721000998 |
News Archive
Agricultural crop production relies on composted waste materials and byproducts, such as animal manure, municipal solid waste composts, and sewage sludge, as a necessary nutrient source.
A study published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, estimates that the prevalence of acute hepatitis C virus (HCV) infection is nearly one percent among newly incarcerated inmates with a history of recent drug use. Findings suggest that systematic screening of intravenous (IV) drug users who are new to the prison system could identify more than 7,000 cases of HCV across the U.S. annually—even among asymptomatic inmates.
ALLOZYNE Inc. announced today the signing of a worldwide, co-exclusive licensing agreement with Sigma-Aldrich giving ALLOZYNE a license for the use of cycloaddition chemistry in the development of therapeutics and diagnostics. Sigma-Aldrich currently holds broad, worldwide intellectual property for the use of cycloaddition chemistry to conjugate biomolecules.
Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Katherine Elizabeth Carrera, NNP 1265 Essex St, Unit 7, San Diego, CA 92103-3323 Ph: (619) 203-9054 | Mrs Katherine Elizabeth Carrera, NNP 3340 Providence Dr, Suite 366, Anchorage, AK 99508-4627 Ph: (907) 563-3026 |
News Archive
Agricultural crop production relies on composted waste materials and byproducts, such as animal manure, municipal solid waste composts, and sewage sludge, as a necessary nutrient source.
A study published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, estimates that the prevalence of acute hepatitis C virus (HCV) infection is nearly one percent among newly incarcerated inmates with a history of recent drug use. Findings suggest that systematic screening of intravenous (IV) drug users who are new to the prison system could identify more than 7,000 cases of HCV across the U.S. annually—even among asymptomatic inmates.
ALLOZYNE Inc. announced today the signing of a worldwide, co-exclusive licensing agreement with Sigma-Aldrich giving ALLOZYNE a license for the use of cycloaddition chemistry in the development of therapeutics and diagnostics. Sigma-Aldrich currently holds broad, worldwide intellectual property for the use of cycloaddition chemistry to conjugate biomolecules.
Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.
› Verified 7 days ago
Ms. Mary Kay Mccarty, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3925 Tudor Centre Dr, #100, Anchorage, AK 99508 Phone: 907-561-8301 Fax: 907-561-8170 | |
Mindy Lorin Schloss, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6852 Cutty Sark St, Anchorage, AK 99502 Phone: 907-243-5936 | |
Katherine L Sterner, A.N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4201 Tudor Centre Dr, Suite 320, Anchorage, AK 99508 Phone: 907-729-4955 | |
Sandra Frenier, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3340 Providence Dr, Suite 452, Anchorage, AK 99508 Phone: 907-562-2120 | |
Janet A Bloch, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3851 Piper St, U340, Anchorage, AK 99508 Phone: 907-562-0321 Fax: 907-562-2683 | |
Lois A Rockcastle, ANP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3801 University Lake Dr Ste 205, Anchorage, AK 99508 Phone: 907-563-1600 Fax: 907-563-0100 | |
Mrs. Megan Renee Hathcoat, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1200 Airport Heights Dr Ste 200, Anchorage, AK 99508 Phone: 907-262-4278 |